We also confirmed the effect of pharmacological blockade of the IGFBP3/TMEM219 signaling/binding in vivo in a DSS-induced acute colitis treatment approach, in which colitis was established first and administration of ecto-TMEM219 was then started at day +3. The gene discussed is TMEM219; the disease is colitis.